Back to today’s briefing

Story perspectives

Global MS Market Growth: New Therapies and Delays Ahead

10/7/2025

34 6

Summary

Story summary

The global MS market is set to grow by 2034 due to rising prevalence.
Key players include Biogen Inc., Sanofi, Immune Response BioPharma; epidemiology shows 728,000 United States MS cases in 2023.
Zydus Lifesciences plans a United States launch of a generic Zeposia for MS.
Sanofi's Tolebrutinib faces a three-month FDA approval delay; PTD802 and PIPE-307 are among new therapies.

1 of 1

Story summary

The global MS market is set to grow by 2034 due to rising prevalence.
Key players include Biogen Inc., Sanofi, Immune Response BioPharma; epidemiology shows 728,000 United States MS cases in 2023.
Zydus Lifesciences plans a United States launch of a generic Zeposia for MS.
Sanofi's Tolebrutinib faces a three-month FDA approval delay; PTD802 and PIPE-307 are among new therapies.